Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(11%)
Results Posted
100%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
8
89%
Ph phase_2
1
11%

Phase Distribution

8

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
8(88.9%)
Phase 2Efficacy & side effects
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (88.9%)
Phase 21 (11.1%)

Trials by Status

active_not_recruiting111%
terminated222%
completed556%
withdrawn111%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_1

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

NCT02952248
terminatedphase_1

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

NCT03780725
completedphase_1

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

NCT03972150
completedphase_1

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

NCT04147234
completedphase_1

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

NCT03990233
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02952248Phase 1

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Completed
NCT03780725Phase 1

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Terminated
NCT03972150Phase 1

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Completed
NCT04147234Phase 1

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Completed
NCT03990233Phase 1

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Completed
NCT04046445Phase 1

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active Not Recruiting
NCT03166631Phase 1

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Terminated
NCT04653142Phase 1

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Completed
NCT04499352Phase 2

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9